Apabetalone (RVX-208) Lowers Risk of Major Adverse Cardiovascular Events (MACE) in T2D Patients with CVD By Attenuating Monocyte Adhesion to Endothelial Cells. (June 2018) - Tsujikawa, Laura; Kulikowski, Ewelina; Calosing, Cyrus; Wasiak, Sylwia; Gilham, Dean; Halliday, Christopher; Johansson, Jan; Sweeney, Mike; Wong, Norm